ubiquinone-q2 and Body-Weight

Effects of in ovo injection of Q10 on hatchability, performance (feed intake (FI), body weight gain (BWG), feed/gain ratio (F/G)) traits, and immune status of Ross × Ross 308 broiler chicks, hatched from eggs laid by a 38-week-old breeder flock, were determined through 42 days after hatch. Eggs containing live embryos were injected in the amnion with 0.1 and 0.2 mL Q10 solution on day 18 of incubation. Two controls groups were included as sham and/or as an uninjected group. At 28 and 42 days of age, performance traits, serum enzyme activity, weights of immune organs, and serum antibody titer of viral diseases were determined. Results were shown that hatchability % increased by Q10 on average of 6.54% (P≤0.025) and body weight/egg weight after hatching increased up to 4.74% (P≤0.002), compared with uninjected and sham controls. Injection of Q10 at different levels led to significant increases (P≤0.001) in performance traits all over the rearing period (P<0.05). Weight of immune organs significantly improved compared to uninjected and sham controls (P<0.05). In addition, serum antibody titers of viral diseases as well as serum enzyme activity of AST, ALT, CAT, and SOD were significantly changed by Q10 treated groups than controls (P≤0.01). In conclusion, in ovo injection of Q10 at levels of 0.1 and 0.2 mL led to significant increases in hatchability%, internal egg characteristics, and performance parameters as well as serum enzyme activity, weight of immune organs, and serum antibody titer of ND, AI, and IBD diseases.

Topics: Animals; Body Weight; Chickens; Eating; Eggs; Female; Injections; Liver; Ovum; Ubiquinone

Obesity is a major risk factor for the onset of type 2 diabetes; however, little is known about the gene(s) involved. Therefore, we developed new animal models of obesity to search for diabetogenic genes associated with obesity. We generated double congenic rat strains with a hyperglycaemic quantitative trait locus (QTL) derived from the Otsuka Long-Evans Tokushima Fatty rat and a fa/fa (Lepr-/-) locus derived from the Zucker Fatty rat; phenotypic analysis for plasma glucose and insulin levels and RNA and protein levels were determined using reverse transcription quantitative PCR and Western blotting analyses, respectively. The double congenic strain F344-fa-nidd2 (Lepr-/- and Nidd2/of) exhibited significantly higher glucose levels and significantly lower hypoglycaemic response to insulin than the obese control strain F344-fa (Lepr-/-). These phenotypes were clearly observed in the obese strains but not in the lean strains. These results indicate that the Nidd2/of locus harbours a diabetogenic gene associated with obesity. We measured the expression of 60 genes in the Nidd2/of QTL region between the strains and found that the mRNA expression levels of five genes were significantly different between the strains under the condition of obesity. However, three of the five genes were differentially expressed in both obese and lean rats, indicating that these genes are not specific for the condition of obesity. Conversely, the other two genes, coenzyme Q2 (Coq2) and placenta-specific 8 (Plac8), were differentially expressed only in the obese rats, suggesting that these two genes are candidates for the onset of type 2 diabetes associated with obesity in rats.

Topics: Animals; Base Sequence; Body Weight; Diabetes Mellitus, Type 2; Disease Models, Animal; Gene Expression; Genetic Association Studies; Genetic Predisposition to Disease; Liver; Male; Obesity; Pregnancy Proteins; Quantitative Trait Loci; Rats, Inbred F344; Sequence Analysis, DNA; Ubiquinone

Coenzyme Q10 (10 mg/kg/day) or digoxin (2 micrograms/kg/day) was given orally to cardiomyopathic hamsters (BIO 14.6) for 8 weeks from 12 weeks of age. The left ventricular weight per gram of body weight (mg/g) was lower (p less than 0.01) in the coenzyme Q10 group (3.09 +/- 0.13) than in the digoxin (3.32 +/- 0.20) and control (3.44 +/- 0.14) groups. Left ventricular function was evaluated in isovolumically beating hearts. Left ventricular developed pressure (63 +/- 5 vs. 54 +/- 10 mmHg, p less than 0.05), -dP/dt (1385 +/- 100 vs. 1211 +/- 136 mmHg/sec, p less than 0.05), and -dP/dt (1068 +/- 126 vs. 896 +/- 141 mmHg/sec, p less than 0.05) were greater in the coenzyme Q10 than in the control group. The time constant of left ventricular relaxation was shorter in the coenzyme Q10 group than in the control group (25 +/- 3 vs. 28 +/- 3 msec, p less than 0.05). By contrast, in the digoxin group, the indices of left ventricular function did not differ from the control group. These results suggest that coenzyme Q10, but not digoxin, attenuated disease progression and preserved left ventricular function in cardiomyopathic hamsters.

Topics: Animals; Body Weight; Cardiac Volume; Cardiomyopathies; Cricetinae; Digoxin; In Vitro Techniques; Mesocricetus; Myocardial Contraction; Ubiquinone; Ventricular Function, Left

Effects of CV-2619 (10 and 30 mg/kg/day, p.o.) or ubiquinone-10 (Q-10, 10 mg/kg/day, p.o.) treatment for 5 weeks on systolic blood pressure (SBP) and myocardial energy metabolism were studied in spontaneously hypertensive rats of 20 weeks of age. The systolic blood pressure was about 205 mmHg at the start of the experiment, and a slight increase was noted thereafter in the control (vehicle) group. CV-2619, but not Q-10, inhibited the increase in the blood pressure. At 25 weeks of age, cardiac hypertrophy was noted to the same extent in either treated group. Myocardial contents of glycolytic intermediates (glycogen, glucose, pyruvate and lactate) and creatine phosphate (Cr-P), ATP, ADP, and AMP were not significantly influenced by CV-2619 or Q-10 treatment. CV-2619, however, significantly increased the energy charge, an index of myocardial energy state, with higher dose and lowered the lactate/pyruvate ratio with either dose. These results suggest that CV-2619 has a mild antihypertensive effect and improves the myocardial energy state in the hypertrophied heart during the sustained phase of hypertension in SHR rats.

Topics: Animals; Benzoquinones; Blood Pressure; Body Weight; Cardiomegaly; Cyclic AMP; Electrocardiography; Energy Metabolism; Heart Rate; Heart Ventricles; Hypertension; Male; Myocardium; Organ Size; Phosphoric Acids; Proteins; Quinones; Rats; Rats, Inbred Strains; Ubiquinone

Antidote actions of CV-2619 and ubiquinone-10 (Q-10) against adriamycin (ADM) cardiotoxicity were studied in spontaneously hypertensive rats. ADM (1 mg/kg/day, i.p.) elicited widening of the QRS complex in the ECG. The widening of the QRS complex was counteracted by a 10-day treatment with CV-2619 (10 and 30 mg/kg/day, p.o.) or Q-10 (10 mg/kg/day, p.o.), which was started on the 15th day of the ADM treatment. CV-2619 or Q-10, however, did not influence ADM-induced decrease in body and heart ventricular weights. Systemic hypotension caused by adriamycin was accelerated by CV-2619 or Q-10. The ADM treatment significantly decreased myocardial glycogen and glucose contents, while it did not affect the lactate content. Furthermore, ADM did not affect the myocardial content of adenine nucleotides, but significantly increased that of creatine phosphate. CV-2619 or Q-10 medication did not counteract changes in these contents by ADM. On the contrary, both agents decreased the lactate content and increased the phosphorylation potential, an index of myocardial energy state. In conclusion, CV-2619 might be as effective as Q-10 to protect the heart against ADM cardiotoxicity, and both test agents improved the myocardial energy state.

Topics: Animals; Benzoquinones; Blood Pressure; Body Weight; Doxorubicin; Electrocardiography; Energy Metabolism; Heart Rate; Heart Ventricles; Hypertension; Male; Myocardium; Organ Size; Phosphoric Acids; Phosphorylation; Proteins; Quinones; Rats; Rats, Inbred Strains; Ubiquinone